Meta Biomed Q1 2026 Report Correction: Adjustments to Allowance for Doubtful Accounts and Inventory Valuation, Treasury Share Cancellation

Correction reason: Error in allowance for doubtful accounts and revaluation of inventory impairment
After correction: Trade receivables (net) 20.34B (end of previous year 17.97B), allowance rate 12.11% (previous year-end 9.65%)
Inventory impairment reversal reduced from 0.79B to 0.14B
Q1 2026 consolidated results: Revenue 24.42B (YoY -11.8%), Operating profit 4.85B (QoQ +88.1%), Net income 4.39B (YoY -22.2%)
Treasury shares cancellation of 922,856 shares completed (board resolution Feb 20, 2026)
Debt ratio improved to 48.36% (previous year-end 49.43%)
Convertible bond balance 3.39B (face value 24B, conversion price 4,795 won), conversion adjustment 2.76B